Objective
to report the clinical outcomes of continuation or interruption of oral anticoagulation during TAVI
Study
international open-label randomised non-inferiority trial
Population
patients who were treated with oral anticoagulation undergoing TAVI
Endpoints
composite of death (cardiovascular), stroke, MI, major vascular complications or major bleeding within 30 days after TAVI
/medias/687723/25-T012_vanGinkel_01.jpg)
/medias/687726/25-T012_vanGinkel_02.jpg)
Conclusion
among patients undergoing TAVI with concomitant oral anticoagulation, continuation was not inferior to interruption of oral anticoagulation.
van Ginkel et al. N Engl J Med. 2024;Online 31 Aug
